Gynecologic Cancer ET743-OVC-3006

April 26, 2017

Sponsor: Janssen Research & Development, LLC

Number: ET743-OVC-3006

The purpose of this study is to assess the efficacy and safety of Trabectedin+DOXIL as a third-line chemotherapy regimen in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy. Third line chemotherapy regimens are treatments given when both initial treatment (first-line therapy) and subsequent treatment (second-line therapy) don’t work, or stop working.

Who’s eligible:

  • The patient must have histologically (tissue microscopically examined) proven advanced-relapsed epithelial ovarian, primary peritoneal ( lining of the abdomen), or fallopian tube cancer. The patient must have received first-line treatment with a platinum-based regimen and had no evidence of disease progression for >= 6 months after the last dose.
  • The patient must have received second-line treatment with a platinum-based regimen, with progression of disease after attaining a response.
  • This study is for women age 18 and older.

Available at: The Hospital of Central Connecticut, Hartford Hospital.

Cancer Clinical Research Office